{"id":226670,"date":"2023-05-26T06:59:18","date_gmt":"2023-05-26T06:59:18","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=226670"},"modified":"2023-05-26T06:59:18","modified_gmt":"2023-05-26T06:59:18","slug":"aadc-inhibitors","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/","title":{"rendered":"Aadc inhibitors"},"content":{"rendered":"<p>Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson&#8217;s disease.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-226670","post","type-post","status-publish","format-standard","hentry","category-a"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aadc inhibitors - Definition of Aadc inhibitors<\/title>\n<meta name=\"description\" content=\"Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson&#039;s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aadc inhibitors - Definition of Aadc inhibitors\" \/>\n<meta property=\"og:description\" content=\"Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson&#039;s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-26T06:59:18+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/\",\"name\":\"Aadc inhibitors - Definition of Aadc inhibitors\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2023-05-26T06:59:18+00:00\",\"dateModified\":\"2023-05-26T06:59:18+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson's disease.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aadc inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aadc inhibitors - Definition of Aadc inhibitors","description":"Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson's disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"Aadc inhibitors - Definition of Aadc inhibitors","og_description":"Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson's disease.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/","og_site_name":"Glossary","article_published_time":"2023-05-26T06:59:18+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/","name":"Aadc inhibitors - Definition of Aadc inhibitors","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2023-05-26T06:59:18+00:00","dateModified":"2023-05-26T06:59:18+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson's disease.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/aadc-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Aadc inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/226670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=226670"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/226670\/revisions"}],"predecessor-version":[{"id":226671,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/226670\/revisions\/226671"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=226670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=226670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=226670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}